MedTrace Logo

Drug Interaction Between Ritonavir And Sitaxsentan

NCT01251848 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-03-05

No results posted yet for this study

Summary

The study is to assess if sitaxsentan and ritonavir will affect the blood levels of each other when coadministered.

Conditions

Interventions

DRUG

Sitaxentan

Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days.

DRUG

Ritonavir

Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days (morning dose only on Day 5).

DRUG

Sitaxsentan

Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days

DRUG

Ritonavir

Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-02-28
Completion
2011-02-28

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01251848 on ClinicalTrials.gov